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Abstract
Purpose Standardized uptake values (SUV) are commonly
used for quantification of whole-body [18F]fluoro-2-deoxy-
D-glucose (FDG) positron emission tomography (PET)
studies. Changes in SUV following therapy, however, only
provide a proper measure of response in case of homoge-
neous FDG uptake in the tumour. The purpose of this study
was therefore to implement and characterize a method that
enables quantification of heterogeneity in tumour FDG
uptake.
Methods Cumulative SUV-volume histograms (CSH), de-
scribing % of total tumour volume above % threshold of
maximum SUV (SUVmax), were calculated. The area under
a CSH curve (AUC) is a quantitative index of tumour
uptake heterogeneity, with lower AUC corresponding to
higher degrees of heterogeneity. Simulations of homoge-
neous and heterogeneous responses were performed to
assess the value of AUC-CSH for measuring uptake and/or
response heterogeneity. In addition, partial volume correc-
tion and image denoising was applied prior to calculating
AUC-CSH. Finally, the method was applied to a number of
human FDG scans.
Results Partial volume correction and noise reduction
improved CSH curves. Both simulations and clinical
examples showed that AUC-CSH values corresponded with
level of tumour heterogeneity and/or heterogeneity in re-
sponse. In contrast, this correspondence was not seen with
SUVmax alone. The results indicate that the main advantage
of AUC-CSH above other measures, such as 1/COV
(coefficient of variation), is the possibility to measure or
normalize AUC-CSH in different ways.
Conclusion AUC-CSH might be used as a quantitative
index of heterogeneity in tracer uptake. In response
monitoring studies it can be used to address heterogeneity
in response.
Keywords Positron emission tomography (PET) .
Standardized uptake value (SUV) . Intratumoural
heterogeneity . Cumulative SUV-volume histogram (CSH) .
Intensity-volume histograms (IVH)
Introduction
In non-small cell lung cancer (NSCLC), positron emission
tomography (PET) has been shown to be a valuable tool not
only for detecting and staging the disease, but also for
response monitoring, prediction of prognosis and estimation
of target volume for radiotherapy purposes [1, 2]. To date,
[18F]fluoro-2-deoxy-D-glucose (FDG) is the most widely
used tracer for oncological applications. Especially for
response monitoring purposes, it is likely that quantitative
assessment of FDG uptake will become the standard. In
general, however, uptake of this tracer is not homogeneously
distributed across the tumour. Factors that may contribute to
intratumoural heterogeneity in FDG uptake are necrosis [3],
cellular proliferation [4], blood flow [5], microvessel density
[6] and hypoxia [7–9]. The standardized uptake value (SUV)
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is most commonly used for (semi-)quantification of whole-
body FDG PET studies [10]. A high maximum SUV
(SUVmax) has been shown to relate to hypoxia and poor
overall survival [11]. However, changes in SUV to assess
response to therapy only provide a proper measure of
response if there is a global change in tracer uptake, i.e. in
the absence of a spatially heterogeneous response. Therefore,
intratumoural FDG heterogeneity may complicate accurate
response assessment with PET. As uptake of a tracer usually
is not homogeneously distributed across the tumour, it is of
interest to quantify heterogeneity in tumour FDG uptake
before, during and after treatment.
Firstly, the distribution of FDG uptake within a tumour
could provide useful information for radiation therapy
treatment planning, as it would allow for specific targeting
of certain areas within the tumour. Secondly, it may provide
additional information when monitoring response, as it
would enable identification of a mixed response within a
single tumour. Finally, differences between CT anatomical
volumes and PET metabolic volumes could be character-
ized. In current clinical practice, however, there is no
simple method for quantification of intratumoural hetero-
geneity in FDG uptake [8].
Only a few methods have been proposed to quantify
intratumoural heterogeneity in FDG uptake. O’Sullivan et al.
[12, 13] proposed a method for patients with sarcoma that
compares the intratumoural FDG uptake distribution with an
elliptic solid object with homogeneous density. Recently,
intensity-volume histograms (IVH) or cumulative SUV-
volume histograms (CSH) have been proposed by El Naqa
et al. [14] as a novel way to characterize heterogeneity in
intratumoural tracer uptake. These histograms are similar to
dose-volume histograms frequently used in radiotherapy
[15]. In CSH the per cent volume of a tumour (derived
from CT or from PET-based (semi-)automatic tumour
delineation methods [16]) with an SUV above a certain
threshold is plotted against that threshold value, which is
varied from 0 to 100% of SUVmax. The area under the CSH
(AUC-CSH) may be a quantitative index of tracer uptake
heterogeneity and/or heterogeneous tumour response [17].
Any method to characterize heterogeneity, however, will
treat both partial volume effects and noise as heterogeneity
and therefore partial volume correction and image denoising
must be applied prior to calculating AUC-CSH [18].
The purpose of this study was to evaluate to which
extent CSH provides additional information about tumour
response (and its heterogeneity) over SUVmax alone. In
addition, the impact of partial volume effects and noise
were evaluated by applying partial volume correction and
image denoising prior to calculating AUC-CSH. To this
end, lung cancer simulations were performed and the
method was applied to several FDG PET studies of tumours
with variable heterogeneity.
Materials and methods
Cumulative SUV-volume histograms
Four strategies for calculating CSH were investigated. As
mentioned above, CSH is normally obtained by plotting the
per cent volume of a tumour with an SUV above a certain
threshold against that threshold, which is varied from 0 to
100% of SUVmax. The AUC of this plot (AUC-CSH) is a
quantitative index of uptake heterogeneity, where lower
values correspond with increased heterogeneity. However,
in this case AUC-CSH is independent of SUVmax and volume,
and therefore it may not be useful for response monitoring,
where changes in SUVmax or metabolic volume should also
be taken into account. To do so, three modifications of CSH
were defined, taking into account changes in metabolic
volume (CSHV), SUVmax (CSH
S) or both (CSHSV). This was
achieved by not plotting relative (percentage) SUVmax or
metabolic volume data, but rather absolute values or values
relative to the baseline SUVmax or volume. Normalized
AUC-CSH values (relative to the baseline) are calculated by:
normalized AUC  CSH ¼ AUC  CSH
response
AUC  CSHbaseline
normalized AUC  CSHV ¼ AUC  CSH
response
AUC  CSHbaseline
 volume
response
volumebaseline
normalized AUC  CSHS ¼ AUC  CSH
response
AUC  CSHbaseline
 SUV
response
max
SUVbaselinemax
normalized AUC  CSHSV ¼ AUC  CSH
response
AUC  CSHbaseline
 SUV
response
max
SUVbaselinemax
 volume
response
volumebaseline
All four strategies were evaluated with and without partial
volume correction and with and without image denoising.
Partial volume correction was performed using image-based
Van Cittert deconvolution (CIT) [19, 20]. During each iterative
deconvolution step (i.e. iteration, five in total) the update of
the image was penalized using a Gibbs prior (weight of 0.25)
applying a neighbourhood of one voxel in all directions [21].
The Gibbs prior calculates the summed difference between
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the central voxel and its direct neighbours. Inclusion of the
prior reduces voxel variability in uniform areas of the image.
Masks that were used to determine metabolic volumes were
eroded with a single voxel in all dimensions to compensate
for remaining sampling error (due to the use of voxels) at the
borders of the masks. In addition, PET images were denoised
using an edge-preserving bilateral filter (BF) [22].
Other parameters to characterize tracer uptake
In addition to AUC-CSH, the following parameters relating to
tumour FDG uptake were also investigated: SUVmax, average
SUV (SUVmean) within a volume of interest (VOI), inverse
standard deviation of SUV within a volume of interest (1/SD)
and inverse coefficient of variation [1/COV, calculated as
(SUVmean/SD)×100%] within the metabolic (i.e. PET-based)
or anatomical (i.e. CT-based) volume.
Simulations
The purpose of the simulations was to evaluate to which
extent CSH provides additional information about tumour
response (and its heterogeneity) over SUVmax alone. In
addition, the impact of partial volume effects and noise
were evaluated by applying partial volume correction and
image denoising prior to calculating AUC-CSH. To this
end, two simulation studies were performed. As a starting
point simulation 1 used a tumour with homogeneous FDG
uptake, while for simulation 2 a tumour with heterogeneous
FDG uptake was used. For both studies, various tumour
responses showing different homogeneous and heteroge-
neous FDG uptake were simulated, as shown in Tables 1
and 2 and Fig. 1. All simulation software was implemented
in-house using IDL (ITT Visual Information Solutions,
Boulder, CO, USA). The effects of randoms and scatter
events were not simulated in this study as this would
require more complex (Monte Carlo-based) simulations.
However, effects of attenuation and resolution were taken
into account.
A 3-D mathematical thorax image and its corresponding
μ-image, used for attenuation correction purposes, were
derived from a dynamic FDG scan of a typical patient, as
described in detail in Boellaard et al. [10]. In short, the
procedure was as follows. For the simulated baseline (BL)
Table 1 Description of the various simulated tumour responses for simulation 1
Response tumour type Code Description of response
No response NR1 Tumour diameter remained at 8 cm with SUV remaining at 6
Homogeneous HO1 Tumour diameter remained at 8 cm with SUV decreasing to 3
HO2 Tumour diameter remained at 8 cm with SUV increasing to 12
HO3 Tumour diameter decreased to 4 cm with SUV remaining at 6
HO4 Tumour diameter decreased to 4 cm with SUV decreasing to 3
HO5 Tumour diameter decreased to 4 cm with SUV increasing to 12
Heterogeneous HE1 Tumour diameter remained at 8 cm with SUV remaining at 6 (outer rim), having an inner core
of 4 cm diameter with an SUV of 3
HE2 Tumour diameter remained at 8 cm with SUV remaining at 6 (outer rim), having an inner core
of 6 cm diameter with an SUV of 3
HE3 Tumour diameter remained at 8 cm with SUV remaining at 6 (outer rim), having an inner core
of 4 cm diameter with an SUV of 12
HE4 Tumour diameter remained at 8 cm with SUV remaining at 6 (outer rim), having an inner core
of 6 cm diameter with an SUV of 12
Table 2 Description of the various simulated tumour responses for simulation 2
Response tumour type Code Description of response
No response NR2 Tumour diameter remained at 8 cm with SUV remaining at 6 (outer rim), having an
inner core of 4 cm diameter with an SUV of 12
Homogeneous HOA Tumour diameter decreased to the inner core of 4 cm diameter with an SUV of 12
HOB Inner core of the tumour increased to 8 cm diameter, remaining at an SUV of 12
Heterogeneous HEA Tumour diameter remained at 8 cm with SUV remaining at 6 (outer rim), having an
inner core of 4 cm diameter with an SUV of 3
HEB Overall tumour SUV decreased by a factor of 2, where tumour diameter remained at
8 cm with SUV decreasing to 3 (outer rim) and an inner core of 4 cm diameter with an SUV of 6
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scans of simulation 1 (BL1), a tumour with homogeneous
FDG uptake was placed within the lungs (SUVmean ~0.6) of
the mathematical thorax image, using a tumour to back-
ground ratio of 10. In addition, various tumours having
homogeneous and heterogeneous FDG uptake were placed
within the lungs of the mathematical thorax image, as shown in
Table 1 and Fig. 1. For the simulated baseline scans of
simulation 2 (BL2), a tumour with heterogeneous FDG
uptake was placed within the lungs of the mathematical
thorax image, using a tumour (outer rim) to background ratio
of 10. In addition, various tumours with homogeneous and
heterogeneous FDG uptake were placed within the lungs of
the mathematical thorax image, as shown in Table 2 and
Fig. 1. For both simulations, these tumours were also placed
in the lungs of the μ-image, having a μ-value equal to that
observed in soft tissue at 511 keV (0.095 cm−1). All of these
Fig. 2 Coronal images of three
clinical examples. Top row: two
PET/CT studies showing various
degrees of uptake heterogeneity
in large lung lesions. Middle
row: PET response study of a
subject with lung cancer. Bottom
row: PET/CT images of a pa-
tient with metastatic liver lesions
before and after treatment
Fig. 1 Axial images of simulated mathematical baseline scans and
various response scans, showing a tumour placed in the left lung. BL
baseline, NRno response, HOhomogeneous tracer uptake, HEhetero-
geneous tracer uptake. Note that these images represent ideal (i.e. free
of noise and partial volume effect) scans. During simulations noise
and partial volume effects were added. For simulation 1, HO and HE
represent homogeneous and heterogeneous responses, respectively.
However, for simulation 2, all HO and HE show heterogeneous
responses, except for HEB that shows a homogeneous response

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images were then forward-projected. Partial volume effects
were introduced by smoothing the obtained sinograms using
a 5-mm full-width at half-maximum (FWHM) Gaussian
kernel. Poisson noise was added to the emission sinograms
obtained. These sinograms were then reconstructed using
normalization and attenuation weighted ordered subsets
expectation maximization (NAW-OSEM) with 4 iterations
and 16 subsets, and post-smoothed using a 5-mm FWHM
Gaussian kernel. The resulting noise level (COV of voxel
values within a VOI ~15%) was similar to that observed in
PET studies acquired on a PET/CT scanner (Gemini TF 64,
Philips Healthcare, Cleveland, OH, USA) [23]. All recon-
structed images consisted of 30 planes of 256×256 voxels
with a voxel size of 2.56×2.56×2.56 mm3. For each tumour
type, 100 noisy simulation images were generated to
investigate accuracy and precision of the various parameters
as described above.
Human studies
Four different human FDG scans were included (Fig. 2). Two
subjects were acquired on a whole-body PET/CT scanner
(Gemini TF 64, Philips Healthcare, Cleveland, OH, USA).
One subject (male, 78 kg, 59 years, 188 MBq FDG
injection) had a primary lung tumour with heterogeneous
uptake, whilst the other (female, 70 kg, 75 years, 184 MBq
FDG injection) had a primary lung tumour with relative
homogeneous uptake. In addition, one subject with a primary
lung tumour (female, 60 years; baseline scan: 57 kg,
163 MBq FDG injection; response scan: 54 kg, 163 MBq
FDG injection) was acquired twice (one scan before and one
scan after one course of chemotherapy) on a whole-body
PET scanner (ECAT EXACT HR+, CTI/Siemens, Knoxville,
TN, USA). Furthermore, one subject with advanced liver
metastases of a gastrointestinal malignancy (male, 65 years;
baseline scan: 71 kg, 566 MBq FDG injection; response
scan: 73 kg, 551 MBq FDG injection) was acquired twice
(one scan before and one scan after three courses of
chemotherapy) on a whole-body PET/CT scanner (Biograph,
CTI/Siemens, Knoxville, TN, USA). All PET and CT data
were collected as part of ongoing clinical studies, which
were approved by an authorized medical Ethics Review
Committee, and informed consent was obtained from each
patient prior to inclusion in the study.
Data analysis
For all simulations and human scans, mean±SD were
calculated for all parameters under investigation. In the case
of the simulations, VOIs were taken from baseline (VOIBL)
scans or redrawn on response (VOIR) scans. For the human
scans, VOIs were drawn using a 50% threshold isocontour
method on baseline PET(/CT) scans and these were then
transformed manually to response scans to obtain a
repositioned VOIBL. In addition, VOIs were drawn using
a 50% threshold isocontour method on the response scans
(VOIR). All uptake (heterogeneity) parameters were calcu-
lated for all VOIs.
Results
Simulations
Noise reduction and partial volume correction
AUC-CSH data obtained from original (i.e. noise and
partial volume free), simulated PET (i.e. with noise and
partial volume effects) and simulated PET with additional
use of bilateral filter and Van Cittert deconvolution (PET+
BF+CIT) are shown in Table 2. A selection of responses is
shown in Fig. 3. Table 3 illustrates that PET+BF+CIT gave
Fig. 3 AUC-CSH (a) and ratio (b) for various types of responses
derived from simulated original (noise and partial volume free), PET
and PET+BF+CIT scans for simulation 1. The ratio was obtained by
dividing AUC-CSH of the response scan by that of the baseline scan
Eur J Nucl Med Mol Imaging (2011) 38:1636–1647 1641
a significant improvement in AUC-CSH compared to PET,
at least when AUC-CSH was normalized to the baseline
AUC-CSH (Student’s t test, p<0.05). Nevertheless, the
actual improvement was rather modest and not significant
for non-normalized data (p=0.10). Figure 4 shows that
CSH curves improve visually after partial volume correc-
tion and noise reduction. More importantly, after image
denoising and partial volume correction, AUC-CSH varied
with the degree of heterogeneity, i.e. lower AUC-CSH
corresponds with a visually more heterogeneous tracer
distribution as well as with the variability of voxel values
within a VOI. Therefore, in the remainder of this article,
only CSH data for PET+BF+CIT images will be provided.
Simulating various response types
Table 4 shows ratios of AUC-CSH (obtained from PET+
BF+CIT images) and several other parameters (obtained
from PET) for various response types. A selection of
responses is shown in Figs. 5 and 6 for simulations 1 and 2,
respectively. These figures also show the effects of various
SUV and volume normalizations on AUC-CSH. Both
Response tumour type Codeb VOIc AUC-CSH
Original PET PET+BF+CIT
Simulation 1
No response NR1 VOIBL 1.00 0.88 0.94
Homogeneous HO1 VOIBL 1.00 0.85 0.91
HO2 VOIBL 1.00 0.91 0.96
HO3 VOIBL 0.31 0.31 0.27
(VOIR) (1.00) (0.89) (0.89)
HO4 VOIBL 0.40 0.40 0.41
(VOIR) (1.00) (0.89) (0.90)
HO5 VOIBL 0.27 0.27 0.22
(VOIR) (1.00) (0.89) (0.88)
Heterogeneous HE1 VOIBL 0.89 0.84 0.89
HE2 VOIBL 0.60 0.79 0.82
HE3 VOIBL 0.61 0.59 0.60
HE4 VOIBL 0.90 0.78 0.82
Simulation 2
No response NR2 VOIBL 0.61 0.59 0.60
Homogeneous HOA VOIBL 0.27 0.27 0.22
(VOIR) (1.00) (0.89) (0.88)
HOB VOIBL 1.00 0.91 0.96
Heterogeneous HEA VOIBL 0.89 0.84 0.89
HEB VOIBL 0.61 0.59 0.60
Table 3 AUC-CSH values of
different tumour responses for
simulated original (i.e. noise and
partial volume free), PET and
PET+BF+CITa images
a Simulated PET with additional
use of bilateral filter and Van
Cittert deconvolution
b Description of the various sim-
ulated tumour responses are giv-
en in Tables 1 (simulation 1) and
2 (simulation 2)
c VOI either defined on baseline
(VOIBL ) or response (VOIR )
scans. VOIR is only provided
when the volume of VOIR is
different from the volume of
VOIBL
Fig. 4 CSHs for baseline and typical homogeneous and heterogeneous responses obtained derived from simulated original (a), PET (b) and PET+BF+
CIT (c) scans for simulation 1. Note that HO1 overlaps with BL1 in (a)
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Table 4 and Figs. 5 and 6 show that normalized values of
AUC-CSH and 1/COV corresponded well with the level of
response heterogeneity, which was not seen using SUVmax,
SUVmean or 1/SD alone.
Simulation 1 (Fig. 5) shows that for homogeneous
responses, normalized (ratio to the baseline) values of
AUC-CSH and 1/COV ranged from 0.93 to 1.02 and from
0.72 to 1.12, respectively, while non-normalized values
ranged from 0.82 to 0.96 and from 0.08 to 0.13, respectively.
For heterogeneous responses, normalized values of AUC-
CSH and 1/COV ranged from 0.64 to 0.94 and from 0.34 to
0.63, respectively, whilst non-normalized values ranged from
0.60 to 0.89 and from 0.04 to 0.07, respectively. AUC-CSHS
showed an increase or decrease when SUVmax increased or
decreased, respectively. Similarly, AUC-CSHV showed an
increase or decrease when volume increased or decreased,
respectively. AUC-CSHSV showed the combined effect of a
change in volume and a change in SUVmax. 1/COV did not
correspond with tumour heterogeneity when data were
obtained from PET+BF+CIT images, where ranges were
between 0.45 and 1.11 and between 0.26 and 0.62 for
homogeneous and heterogeneous responses, respectively.
Simulation 2 (Fig. 6) also shows that AUC-CSH and 1/
COV of a homogeneous response (HEB, 1.01 and 1.00,
respectively), normalized to the baseline, falls within the
same range as for simulation 1. Responses that show an
increase in homogeneity showed an increase in normalized
AUC-CSH and 1/COV, ranging from 1.47 to 1.60 and from
1.86 to 3.32, respectively. For non-normalized AUC-CSH
and 1/COV, this trend was not observed (increase in
homogeneity: 0.88–0.96 and 0.07–0.13, respectively; ho-
mogeneous response: 0.60 and 0.04, respectively).
Human studies
Figure 7 shows CSHs for the four clinical scans shown in
Fig. 2. Values of the various parameters are shown in
Table 5. For the diagnostic lung studies, AUC-CSH
correctly indicated heterogeneity for the tumour with more
heterogeneous uptake (0.47) and a more homogeneous
distribution for the homogeneous one (0.79). For the
response studies, AUC-CSH indicated an increase in
heterogeneity (AUC-CSH: 0.74 to 0.63) for the lung
tumour (Fig. 2, second row), whilst a decrease in
Table 4 Ratios of AUC-CSH (derived from PET+BF+CITa), SUVmax, SUVmean 1/SD and 1/COV (derived from PET) for different tumour
responses. All values are normalized to the baseline scan
Response tumour type Codeb VOIc AUC-CSH AUC-CSHS AUC-CSHV AUC-CSHSV SUVmax SUVmean 1/SD 1/COV Volume
Simulation 1
No response NR1 VOIBL 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Homogeneous HO1 VOIBL 0.97 0.49 0.97 0.49 0.52 0.50 3.13 0.88 1.00
HO2 VOIBL 1.02 2.04 1.02 2.04 1.96 2.01 0.31 1.12 1.00
HO3 VOIBL 0.29 0.26 0.29 0.26 0.89 0.31 0.14 0.12 1.00
(VOIR) (0.94) (0.83) (0.12) (0.10) (0.89) (0.90) (0.64) (0.72) (0.13)
HO4 VOIBL 0.43 0.18 0.43 0.18 0.44 0.20 0.81 0.18 1.00
(VOIR) (0.95) (0.39) (0.12) (0.05) (0.44) (0.44) (2.80) (0.74) (0.13)
HO5 VOIBL 0.23 0.43 0.23 0.43 1.81 0.55 0.03 0.09 1.00
(VOIR) (0.93) (1.72) (0.12) (0.22) (1.81) (1.84) (0.16) (0.74) (0.13)
Heterogeneous HE1 VOIBL 0.94 0.89 0.94 0.89 0.93 0.88 0.50 0.63 1.00
HE2 VOIBL 0.88 0.65 0.88 0.65 0.73 0.65 0.88 0.61 1.00
HE3 VOIBL 0.64 1.18 0.64 1.18 1.84 1.23 0.07 0.34 1.00
HE4 VOIBL 0.87 1.71 0.87 1.71 1.93 1.70 0.07 0.44 1.00
Simulation 2
No response NR2 VOIBL 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Homogeneous HOA VOIBL 0.37 0.36 0.37 0.36 0.98 0.44 0.40 0.28 1.00
(VOIR) (1.47) (1.46) (0.18) (0.18) (0.98) (1.49) (2.15) (2.19) (0.13)
HOB VOIBL 1.60 1.73 1.60 1.73 1.06 1.63 4.13 3.32 1.00
Heterogeneous HEA VOIBL 1.48 0.75 1.48 0.75 0.51 0.72 6.72 1.86 1.00
HEB VOIBL 1.01 0.49 1.01 0.49 0.50 0.50 4.05 1.00 1.00
a Simulated PET with additional use of bilateral filter and Van Cittert deconvolution
b Description of the various simulated tumour responses are given in Tables 1 (simulation 1) and 2 (simulation 2)
c VOI either defined on baseline (VOIBL ) or response (VOIR ) scans. VOIR is only provided when the volume of VOIR is different from the
volume of VOIBL
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heterogeneity (AUC-CSH: 0.18 to 0.40) was seen for the
liver metastases (Fig. 2, second row). All the increases and
decreases of AUC-CSH were in agreement with visual
interpretation. Similar trends were observed for 1/COV.
Discussion
Both partial volume effects and image noise will lead to
apparent tumour heterogeneity, and a correction for these
confounding effects is needed for accurate calculation of
measures that quantify tumour heterogeneity. Partial volume
effects could prevent identification of the origin of counts in
voxels, as these consist of average values of which the origin is
not always known. For example, low uptake of FDG in a voxel
could be the result of well oxygenated tumour tissue (with low
and uniform FDG uptake) or averaging over a regionwith both
hypoxic (high FDG uptake) and necrotic (low FDG uptake)
tissue [8]. Although partial volume effects are unavoidable
due to the limited resolution of PET, they need to be
corrected for as much as possible. Recently, Hoetjes et al.
[20] showed that image-based Van Cittert deconvolution is
useful for partial volume correction in oncology. The results
of the present study showed that a Van Cittert deconvolution
with Gibbs prior, in combination with bilateral filtering to
limit spatial noise, did improve CSH curves visually (Fig. 4)
and improved accuracy of AUC-CSH (Fig. 3 and Table 3).
The simulations showed that both AUC-CSH and 1/COV
corresponded well with level of tumour heterogeneity or
heterogeneous response, in contrast to SUVmax, SUVmean or
1/SD (Fig. 5 and Table 4). This means that a change in
AUC-CSH corresponded with a visual apparent change in
tracer uptake distribution as well as with the variability of
voxel values within a tumour. Although the latter can be
expressed by COV (%) of voxel values, AUC-CSH might
Fig. 6 Ratio of various types of AUC-CSH (a) and SUVmax,
SUVmean, 1/SD and 1/COV (b) for various types of responses for
simulation 2. AUC-CSH and other uptake parameters were derived
from simulated PET+BF+CIT and PET response images, respectively.
The ratio for each parameter was obtained by dividing its value from the
response scan by that from the baseline scan
Fig. 5 Ratio of various types of AUC-CSH (a) and SUVmax,
SUVmean, 1/SD and 1/COV (b) for various types of responses for
simulation 1. AUC-CSH and other uptake parameters were derived
from simulated PET+BF+CIT and PET response images, respectively.
The ratio for each parameter was obtained by dividing its value from the
response scan by that from the baseline scan
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have the additional advantage of exploring changes in tracer
uptake distribution relative to baseline distribution, i.e. to
normalize the x- and y-axis to baseline volume and SUVmax,
respectively. In practice, this means that 100% corresponds
to the metabolic volume (y-axis) and SUVmax (x-axis)
observed in the baseline study. When such normalization is
applied, tumour growth would result in a CSH that goes
beyond the 100% on the y-axis. Likewise, an increase of
SUVmax means that the CSH would go beyond the 100% of
the x-axis. Thus, visual representation of CSH curves for
baseline and response studies in one plot can then assist in a
quick interpretation of both metabolic volume and tracer
uptake changes. Note that a change in AUC-CSH, when both
axes are normalized to the baseline, equals that of the total
lesion glycolysis (TLG, calculated as the product of SUVmean
and volume). However, a constant TLG could still be seen
when tumour size has increased with a corresponding
decrease in SUV. Use of normalized CSH would also
demonstrate a constant AUC-CSH (Fig. 8), but would
provide CSH curves with different shapes. By not renorm-
alizing CSH (i.e. CSH is generated using the tumour volume
and SUVmax of the image being analysed) an index for tracer
heterogeneity or tracer uptake variability over the tumour at
that time is obtained. These different normalizations may be
useful for response monitoring, as they provide additional
information on the response. The type of normalization of
AUC-CSH that would be clinically most relevant needs to be
further assessed in future studies.
CSH could be used for various applications. The focus of
the present study was measurement of heterogeneity in FDG
uptake in an NSCLC tumour. Two clinical examples (Figs. 2
and 7 and Table 5) indicate that AUC-CSH can quantify the
degree of heterogeneity in FDG uptake, both at baseline
(diagnostic studies) and as a result of therapy (response
studies). For response studies, VOIs could be defined on
either baseline or response scans. Definition of VOI on the
baseline and response scans might identify increase in
necrotic tissue tumour after treatment. Definition of VOI on
the response scan would indicate whether overall heteroge-
neity in FDG uptake of the tumour had changed in the
presence of a volume change. The definition that would be
clinically most relevant needs to be further assessed in future
Table 5 AUC-CSH, SUVmax, SUVmean 1/SD and 1/COV data for the four human scans shown in Fig. 2, as obtained from PET+BF+CIT
a images
Study Type VOIb AUC-CSH AUC-CSHS AUC-CSHV AUC-CSHSV SUVmax SUVmean 1/SD 1/COV Volume (ml)
Diagnostic
lung study
Homogeneous VOIBL 0.79 6.7 93 780 13.2 10.5 0.48 0.06 120
Heterogeneous VOIBL 0.47 2.0 91 390 5.9 2.8 0.64 0.02 200
Response
lung study
Baseline VOIBL 0.74 6.7 28 250 9.1 6.7 0.41 0.043 37
Response VOIBL 0.63 1.9 23 71 3.1 1.9 2.6 0.031 37
(VOIR) (0.64) (2.0) (28) (84) (3.1) (2.0) (3.0) (0.034) (43)
Response
liver study
Baseline VOIBL 0.18 3.9 370 7,900 38 6.7 0.064 0.013 2,000
Response VOIBL 0.40 2.3 800 4,600 7.9 3.2 1.2 0.028 2,000
(VOIR) (0.45) (2.6) (710) (4,100) (7.9) (3.6) (2.1) (0.044) (1,600)
a Simulated PET with additional use of bilateral filter and Van Cittert deconvolution
b VOI either defined on baseline (VOIBL ) or response (VOIR ) scans. VOIR is only provided for response studies
Fig. 7 CSHs for diagnostic lung study (a), response lung study (b)
and response liver study (c). VOIs of response scans were either
defined on the baseline scan (VOIBL) or on the response scan (VOIR).
The AUC-CSH and/or its change corresponded well with various
degrees of tracer uptake heterogeneity and/or its change
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studies. Another application might be assessment of response
across multiple metastatic lesions, such as in the liver. The
liver often contains many metastatic lesions, which are
difficult to monitor individually. In these cases AUC-CSH
could be used to characterize a global change in tumour load
in combination with e.g. TLG [24]. Finally, CSH and
AUC-CSH may be used to characterize differences between
CT-based anatomical and PET-based metabolic tumour
volumes and/or tracer distributions, i.e. a high AUC-CSH
would indicate a good correspondence between CT tumour
volume and tracer distribution, whilst a low AUC-CSH
indicates a large discrepancy between CT tumour volume
and PET tracer distribution.
To the best of our knowledge, this is the first study that
attempts to characterize and quantify heterogeneity of tracer
uptake using the AUC-CSH and different normalizations. The
performance of the proposed method was assessed using
simulations, and a few clinical cases were used to illustrate the
performance of the method and different normalizations.
Future studies need to address the potential clinical value of
CSH and are aimed at test-retest studies as well as the
application of the method on larger clinical data sets.
Furthermore, it would be ideal to have a database or
benchmark data set containing more realistically simulated
anthropomorphic PET images based on e.g. Monte Carlo
simulations [25, 26]. This would allow one to not only more
extensively explore uptake heterogeneity measures but also
to validate new tumour segmentation algorithms. The
proposed method for parameterizing uptake heterogeneity is
not spatially invariant, unlike the method proposed by
O’Sullivan et al. [12]. For patients with sarcoma, this method
that assesses spatial intratumoural heterogeneity in FDG
uptake has been shown to be a predictor of patient outcome
[27]. However, preliminary studies already indicated that
other measures derived from the CSH, such as the % of
volume derived at a fixed % of SUVor % of SUV derived at
a fixed % of volume, could be used as a prognostic factor in
NSCLC [28] and head and neck cancer [14]. In addition,
further studies are needed to assess the value of the different
methods to normalize these CSH to baseline values (SUV
and/or volume). Nevertheless, the present preliminary results
might indicate the potential value of CSH and AUC-CSH
characterizing metabolic tumour heterogeneity.
Conclusion
These initial results indicate that AUC-CSH might be used
as a quantitative index of heterogeneity in tracer uptake and
it can be used as a means to address (changes in)
heterogeneity in response assessment studies. In addition,
the results show that a Van Cittert deconvolution with
Gibbs prior, in combination with bilateral filtering to limit
spatial noise, improves the CSH curves visually.
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